(Q28278957)

https://api.crossref.org/works/10.1179/ACB.2010.002

Increased body fat mass and decreased extracellular fluid volume in adults with growth hormone deficiency

21 April 2017

2 references

https://api.crossref.org/works/10.1179/ACB.2010.002

21 April 2017

https://api.crossref.org/works/10.1179%2FACB.2010.002

Differential effect sizes of growth hormone replacement on Quality of Life, well-being and health status in growth hormone deficient patients: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179/ACB.2010.002

Preparation of growth hormone from pituitaries of man and monkey

21 April 2017

1 reference

https://api.crossref.org/works/10.1179%2FACB.2010.002

Beneficial effects of growth hormone treatment in GH-deficient adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2010.002

The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2010.002

Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults - a KIMS database analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2010.002

Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinol

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2010.002

Growth hormone therapy in adults and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2010.002

Isolated growth hormone deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2010.002

Anterior pituitary dysfunction following traumatic brain injury (TBI).

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2010.002

Endocrine and metabolic disorders in young adult survivors of childhood acute lymphoblastic leukaemia (ALL) or non-Hodgkin lymphoma (NHL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2010.002

Approach to the growth hormone-deficient child during transition to adulthood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2010.002

A nationwide attempt to standardize growth hormone assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2010.002

Diagnosis of adult GH deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2010.002

Clinical aspects of growth hormone deficiency in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2010.002

Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2010.002

Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical Practice Guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2010.002

Decreased psychological well-being in adult patients with growth hormone deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2010.002

Application of a disease-specific, quality-of-life measure (QoL-AGHDA) in growth hormone-deficient adults and a random population sample in Sweden: validation of the measure by rasch analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2010.002

Quality of life assessment of growth hormone deficiency in adults (QoL-AGHDA): comparison of normative reference data for the general population of England and Wales with results for adult hypopituitary patients with growth hormone deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2010.002

Baseline characteristics and the effects of five years of GH replacement therapy in adults with GH deficiency of childhood or adulthood onset: a comparative, prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2010.002

Increased fracture frequency in adult patients with hypopituitarism and GH deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2010.002

The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. .

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2010.002

Growth hormone and the heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2010.002

The severity of growth hormone deficiency correlates with the severity of cardiac impairment in 100 adult patients with hypopituitarism: an observational, case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2010.002

Low-density lipoprotein apolipoprotein B100 turnover in hypopituitary patients with GH deficiency: a stable isotope study

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2010.002

Growth hormone-deficient adults are insulin-resistant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2010.002

Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2010.002

Premature mortality due to cardiovascular disease in hypopituitarism

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2010.002

Increased cerebrovascular mortality in patients with hypopituitarism

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2010.002

Growth hormone therapy for adults: not ready for prime time?

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2010.002

Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2010.002

Reduced longevity in untreated patients with isolated growth hormone deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2010.002

Management of growth hormone deficiency in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2010.002

Growth hormone (GH) replacement therapy in adult-onset gh deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2010.002

A 10-year, prospective study of the metabolic effects of growth hormone replacement in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2010.002

Effects of 10 years of growth hormone (GH) replacement therapy in adult GH-deficient men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2010.002

The effects of growth hormone replacement therapy on bone metabolism in adult-onset growth hormone deficiency: a 2-year open randomized controlled multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2010.002

Growth hormone decreases visceral fat and improves cardiovascular risk markers in women with hypopituitarism: a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2010.002

Ten-year GH replacement increases bone mineral density in hypopituitary patients with adult onset GH deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2010.002

Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a Metaanalysis of Blinded, Randomized, Placebo-Controlled Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2010.002

Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2010.002

Can growth hormone therapy cause diabetes? KIMS Strategic Committee.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2010.002

Cardiac effects of growth hormone in adults with growth hormone deficiency: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2010.002

Does long-term GH replacement therapy in hypopituitary adults with GH deficiency normalise quality of life?

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2010.002

Two years of replacement therapy in adults with growth hormone deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2010.002

Which adults develop side-effects of growth hormone replacement?

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2010.002

GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2010.002

Safety of GH replacement in hypopituitary patients with nonirradiated pituitary and peripituitary tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2010.002

Long-term experience with GH replacement therapy: efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2010.002

Effect of recombinant human growth hormone (GH) replacement on the hypothalamic-pituitary-adrenal axis in adult GH-deficient patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2010.002